← Back to Search

Monoclonal Antibodies

SGN-CD228A for Colorectal Cancer

Phase 1
Waitlist Available
Research Sponsored by Seagen Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 3.5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test SGN-CD228A, a new drug, to see if it can safely treat patients with advanced solid tumors by stopping tumor growth or reducing their size.

Eligible Conditions
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Mesothelioma
  • Pancreatic Cancer
  • Skin Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 3.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 3.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with adverse events
Secondary study objectives
Duration of complete response
Duration of objective response (DOR)
Objective response rate (ORR)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SGN-CD228AExperimental Treatment1 Intervention
SGN-CD228A monotherapy

Find a Location

Who is running the clinical trial?

Seagen Inc.Lead Sponsor
210 Previous Clinical Trials
74,342 Total Patients Enrolled
Phillip Garfin, MD, PhDStudy DirectorSeagen Inc.
3 Previous Clinical Trials
175 Total Patients Enrolled
Anu Gupta, MDStudy DirectorSeagen Inc.
1 Previous Clinical Trials
58 Total Patients Enrolled
~14 spots leftby Nov 2025